Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.

This article reviews the steps that have led us from very fundamental research on the cell division cycle, investigated with the starfish oocyte model, to the identification of drugs now being evaluated against cancer in the clinic. Among protein kinases activated during entry in M phase, the cyclin-dependent kinase CDK1/cyclin B was initially identified as a universal M-phase promoting factor. It was then used as a screening target to identify pharmacological inhibitors. The first inhibitors to be discovered were 6-dimethylaminopurine and isopentenyladenine, from which more potent and selective inhibitors were optimized (olomoucine, roscovitine, and purvalanols). All were cocrystallized with CDK2 and found to localize in the ATP-binding pocket of the kinase. Their selectivity and cellular effects have been thoroughly investigated. Following encouraging results obtained in preclinical tests and favorable pharmacological properties, one of these purines, roscovitine (CYC202), is now entering phase II clinical trials against cancers and phase I clinical tests against glomerulonephritis. CDK inhibitors are also being evaluated, at the preclinical level, for therapeutic use against neurodegenerative diseases, cardiovascular disorders, viral infections, and parasitic protozoa. This initially unexpected scope of potential applications and the large number and chemical diversity of pharmacological inhibitors of CDKs now available constitute a very encouraging stimulus to pursue the search for optimization and characterization of protein kinase inhibitors, from which we expect numerous therapeutic applications.

[1]  Jane A. Endicott,et al.  Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor , 2002, Nature Structural Biology.

[2]  C. W. Parker,et al.  Inhibitors of two enzymes which metabolize cytokinins , 1986 .

[3]  Paul Greengard,et al.  Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.

[4]  T. Kishimoto.  Activation of MPF at meiosis reinitiation in starfish oocytes. , 1999, Developmental biology.

[5]  L. Rebhun,et al.  Cleavage inhibition in marine eggs by puromycin and 6-dimethylaminopurine. , 1973, Experimental cell research.

[6]  P. Schultz,et al.  Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. , 1999, Chemistry & biology.

[7]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[8]  D. Altieri,et al.  A p34(cdc2) survival checkpoint in cancer. , 2002, Cancer cell.

[9]  L. Meijer,et al.  ATP-site directed inhibitors of cyclin-dependent kinases. , 1999, Current medicinal chemistry.

[10]  J. Labbé,et al.  MPF from starfish oocytes at first meiotic metaphase is a heterodimer containing one molecule of cdc2 and one molecule of cyclin B. , 1989, The EMBO journal.

[11]  J. Sedivy,et al.  c-Myc Is Necessary for DNA Damage-Induced Apoptosis in the G2 Phase of the Cell Cycle , 2001, Molecular and Cellular Biology.

[12]  L. Meijer,et al.  cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF , 1988, Cell.

[13]  E. Krebs,et al.  Characterization of maturation-activated histone H1 and ribosomal S6 kinases in sea star oocytes. , 1987, Biochemistry.

[14]  L. Meijer,et al.  Maturation and fertilization in starfish oocytes. , 1984, International review of cytology.

[15]  P G Schultz,et al.  A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[17]  A. Borgne,et al.  The role of cyclin-dependent kinases in apoptosis. , 2003, Progress in cell cycle research.

[18]  L. Meijer,et al.  Stimulation of protein phosphorylation during fertilization-induced maturation of Urechis caupo oocytes. , 1982, Developmental biology.

[19]  L. Meijer,et al.  Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. , 1988, Experimental cell research.

[20]  P. Guerrier,et al.  6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. , 1988, Experimental cell research.

[21]  S. Døskeland,et al.  A Novel, Extraneuronal Role for Cyclin-dependent Protein Kinase 5 (CDK5) , 2002, The Journal of Biological Chemistry.

[22]  E. Schierenberg,et al.  Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases , 1995, Biology of the cell.

[23]  E. Goldsmith,et al.  Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.

[24]  J Mottram,et al.  Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. , 2000, Chemistry & biology.

[25]  I. Hardcastle,et al.  Designing inhibitors of cyclin-dependent kinases. , 2002, Annual review of pharmacology and toxicology.

[26]  L. Meijer,et al.  p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol , 2002, Oncogene.

[27]  J. Mester,et al.  Cellular effects of purvalanol A: A specific inhibitor of cyclin‐dependent kinase activities , 2002, International journal of cancer.

[28]  L. Meijer,et al.  A starfish oocyte user's guide , 1984 .

[29]  L. Meijer,et al.  Starfish oocyte maturation: from prophase to metaphase , 1994 .

[30]  E. Krebs,et al.  Differential regulation of histone H1 and ribosomal S6 kinases during sea star oocyte maturation. , 1987, Biochemistry.

[31]  L. Meijer,et al.  Protein phosphorylation and oocyte maturation: I. Induction of starfish oocyte maturation by intracellular microinjection of a phosphatase inhibitor, α-naphthylphosphate☆ , 1986 .

[32]  A. Bitonti,et al.  Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. , 2001, Journal of medicinal chemistry.

[33]  Donald E Ingber,et al.  Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV‐1 envelope , 2002, The EMBO journal.

[34]  D. Wong,et al.  Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. , 2002, International journal of oncology.

[35]  L. Meijer,et al.  Cyclin is a component of the sea urchin egg M‐phase specific histone H1 kinase. , 1989, The EMBO journal.

[36]  Y. Masui.  A quest for cytoplasmic factors that control the cell cycle. , 1996, Progress in cell cycle research.

[37]  L Meijer,et al.  Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. , 1998, Bioorganic & medicinal chemistry letters.

[38]  A. Bitonti,et al.  THE DESIGN AND SYNTHESIS OF PURINE INHIBITORS OF CDK2. III , 2001 .

[39]  L. Meijer,et al.  Intracellular targets of paullones : identification by affinity chromatography using immobilized inhibitor. , 2002 .

[40]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[41]  L. Meijer,et al.  Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral, Proteins , 2002, Journal of Virology.

[42]  J. Clough.  CDK inhibitor shows promise for inflammatory kidney disease. , 2002, Drug discovery today.

[43]  L Meijer,et al.  Multiple modes of ligand recognition: Crystal structures of cyclin‐dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine , 1995, Proteins.

[44]  F. Tamanoi,et al.  Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines , 2000, Oncogene.

[45]  K. Nakanishi,et al.  Isolation and Identification of Meiosis Inducing Substance in Starfish Asterias amurensis , 1969, Nature.

[46]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[47]  N. Jullian,et al.  Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future. , 2002, Current topics in medicinal chemistry.

[48]  L. Meijer,et al.  The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. , 1998, Experimental cell research.

[49]  L. Meijer,et al.  Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. , 1997, The Journal of clinical investigation.

[50]  A. Skoultchi,et al.  Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Beach,et al.  Activation of M-phase-specific histone H1 kinase by modification of the phosphorylation of its p34cdc2 and cyclin components. , 1990, Genes & development.

[52]  Laurent Meijer,et al.  Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. , 2002, Biochemical pharmacology.

[53]  L. Meijer,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors , 2001, Journal of Virology.

[54]  H. Tung,et al.  Protein phosphorylation and oocyte maturation. II. Inhibition of starfish oocyte maturation by intracellular microinjection of protein phosphatases 1 and 2A and alkaline phosphatase. , 1986, Experimental cell research.

[55]  H. Yoshida,et al.  Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition , 2002, Nature Cell Biology.

[56]  L. Meijer.  HORMONAL CONTROL OF OOCYTE MATURATION IN ARENICOLA MARINA L. (ANNELIDA, POLYCHAETA) I. MORPHOLOGICAL STUDY OF OOCYTE MATURATION , 1979 .